

## PeptiDream enters into strategic partnership with PharmalN

06 June 2019 | News

PeptiDream will broadly use PharmalN's PGC™ technology across its discovery programs to formulate applicable therapeutic peptides with PGC™ and evaluate in vivo the drug carrier/delivery benefits



PeptiDream, a public Kanagawa-based biopharmaceutical company has recently announced a strategic partnership with PharmalN Corporation ("PharmalN") for the purpose of investigating the use of PharmalN's proprietary drug carrier and delivery Protected Graft Co-Polymer ("PGC™") technology in combination with PeptiDream's peptide discovery and development programs.

PharmalN's breakthrough PGC™ technology is a PEG-based excipient that reversibly binds the therapeutic peptide and unlike PEGylation or other peptide PK extending technologies, does not require the peptide to be modified in anyway, thereby fully preserving the potency, function, and mobility of the therapeutic peptide payload. Additionally, the PGC™ technology offers a number of other potentially significant advantages in that it can improve the solubility of the peptide payload, protects the peptide payload from degradation, thereby increasing stability, and acts to slowly releases the peptide payload resulting in a significantly longer circulation half-life. The PGC™ technology has also shown to passively target the peptide payload to tumor sites/ sites of inflammation/infection and can significantly decrease the risk of injection site reactions common to conventional injectables.

Under the partnership, PeptiDream will have the ability to broadly use PharmalN's PGC™ technology across its discovery programs to formulate applicable therapeutic peptides with PGC™ and evaluate *in vivo* the drug carrier/delivery benefits. Clinical development and commercialization of any peptide employing PharmalN's PGC™ technology would require a specific development and commercialization license.